Director General Speeches

Milestones :: Perspectives :: Research

 

Director General Speeches

22 October 2021
Speech
WHO Director-General’s opening remarks at the 9th meeting of the IHR Emergency Committee on COVID-19 – 22 October 2021
…Inequitable access to vaccines and other life-saving tools means that a large proportion of the world’s population remains susceptible to infection and at increased risk of severe disease and death.
As you know, we have set a target to vaccinate 40% of the population of every country by the end of this year. 82 countries are at risk of missing that target. For most of those countries, it’s simply a problem of insufficient and unpredictable supply. A small group of countries have some limitations in their ability to absorb vaccines, and we are working to address those problems.
Recent months have also shown the importance of monitoring vaccine protection.
Data show that vaccines slow but don’t fully stop transmission; however, they are very effective at protecting against symptomatic and severe disease as well as hospitalization and death caused by the Delta variant.
However, given the still-unknown benefits of revaccinating the general population, WHO has decided that additional doses should be targeted to at-risk population groups, such as those who are immunocompromised and older people…

21 October 2021
Speech
WHO Director-General’s opening remarks at the media briefing on COVID-19 – 21 October 2021

21 October 2021
Speech
Director-General’s opening remarks at Member States Information Session on COVID-19 – 21 October 2021

19 October 2021
Keynote
Director-General’s speech on building health systems resilience during COVID-19 and beyond

 

::::::
::::::

Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 29 September 2021
For 23 vaccine candidates, presents Manufacturer, Name of Vaccine, NRA of Record, Platform, EOI Accepted Status, Pre-submission Meeting Held Status, Dossier Accepted for Review, Status of Assessment; Anticipated/Completed Decision Date
[Full scale view available at title ling above]

 

::::::

COVID Vaccine Developer/Manufacturer Announcements
[relevant press releases/announcement from organizations from WHO EUL/PQ listing above]

 

AstraZeneca
Press Releases – No new digest announcements identified

BioCubaFarma – Cuba
Últimas Noticias – [Website not responding at inquiry; receiving 403-Forbidden]

 

CanSinoBIO
News – [Website not responding at inquiry]

Clover Biopharmaceuticals – China
News – No new digest announcements identified

 

Curevac [Bayer Ag – Germany]
News – No new digest announcements identified

 

Gamaleya National Center
Latest News and Events – No new digest announcements identified [See Russia/RFID below]

IMBCAMS, China
Home – No new digest announcements identified

 

Janssen/JNJ
Press Releases
Oct 21, 2021 United States
U.S. CDC Advisory Committee Unanimously Recommends Johnson & Johnson COVID-19 Vaccine as a Booster for All Eligible Individuals Who Receive Authorized COVID-19 Vaccines

Oct 20, 2021 United States
Johnson & Johnson COVID-19 Vaccine Booster Shot Authorized for Emergency Use by U.S. FDA

Oct 18, 2021 United States
17 Million Doses of Johnson & Johnson COVID-19 Vaccine to be Donated to African Union Countries

Oct 15, 2021 United States
Johnson & Johnson COVID-19 Vaccine Booster Shot Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee

 

Moderna
Press Releases
October 21, 2021
U.S. CDC Advisory Committee on Immunization Practices Recommends Booster Vaccination with Moderna’s COVID-19 Vaccine

October 20, 2021
Moderna Announces FDA Authorization of a Booster Dose of Moderna’s COVID-19 Vaccine in the U.S.

October 14, 2021
Moderna Announces FDA Advisory Committee Unanimously Votes in Support of Emergency Use for a Booster Dose of Moderna’s COVID-19 Vaccine in the U.S.

October 14, 2021
Moderna Announces COVAX Exercises Option to Purchase 176.5 Million Additional Doses of Moderna’s COVID-19 Vaccine for Low Income Countries in First Half of 2022

 

Novavax
Press Releases
Novavax Statement on Initial Com-COV2 Phase 2 Clinical Trial Results Presented at World Vaccine Congress Europe Oct 19, 2021

 

Pfizer
Recent Press Releases
10.20.2021
Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine

10.20.2021
Advisory Committee on Immunization Practices Votes to Recommend Routine Use of Pfizer’s PREVNAR 20™ (Pneumococcal 20-valent Conjugate Vaccine) in Adults

 

Sanofi Pasteur
Press Releases – No new digest announcements identified

 

Serum Institute of India
NEWS & ANNOUNCEMENTS – No new digest announcements identified

 

Sinopharm/WIBPBIBP
News – No new digest announcements identified

 

Sinovac
Press Releases – No new digest announcements identified

 

Vector State Research Centre of Viralogy and Biotechnology
Home – No new digest announcements identified

Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]
[No website identified]

 

::::::

GSK
Press releases for media
US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices votes unanimously to recommend Shingrix for immunocompromised adults aged 19 and up
20 October 2021

 

Merck
News releases
CDC ACIP Unanimously Votes to Provisionally Recommend Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Series with PNEUMOVAX ® 23 (Pneumococcal Vaccine Polyvalent) as an Option for Pneumococcal Vaccination in Appropriate Adults
October 29, 2021

Merck and Ridgeback Announce Submission of Emergency Use Authorization Application to the U.S. FDA for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in At Risk Adults
October 15, 2021

 

Novartis
News
Novartis signs new initial agreement with BioNTech to support fill and finish of the mRNA Pfizer-BioNTech COVID-19 vaccine
Oct 21, 2021
:: At least 24 million doses of the mRNA-based vaccine will be filled in 2022 into vials under sterile conditions at Novartis Technical Operations state-of-the-art facility in Ljubljana, Slovenia
:: New agreement follows earlier supply agreement for the fill and finish of more than 50 million doses in 2021 at the Novartis Stein site in Switzerland

 

SK Biosciences
Press releases – No new digest announcements identified